Cite
HARVARD Citation
Gogishvili, M. et al. (n.d.). Patient-reported outcomes (PROs) of cemiplimab (CEMI) versus platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%: A focus on EMPOWER-Lung 1 (NCT03088540) age subgroups. Journal of geriatric oncology. pp. S3-. [Online].